Devonian Health Group (GSD) Q2 2026 earnings summary

Executive summary

• Reported a net loss of $2.2 million ($0.81 per share) for Q2 2026 and $3.8 million ($1.37 per share) for the six months ended January 31, 2026.

• Cash position as of January 31, 2026, was $1.3 million; the company remains debt-free.

• Completed a 1-for-60 reverse stock split on January 22, 2026.

• Strategic focus shifted to biopharmaceutical development centered on Thykamine™, with ongoing preclinical and pivotal clinical studies.

• Board and executive changes included new appointments for Board Director, Audit Committee Chair, and CFO.

Financial highlights

• Q2 2026 net loss increased by $2 million year-over-year, mainly due to lower distribution revenues after the Dexlansoprazole agreement expiry.

• Six-month net loss rose by $3 million year-over-year, with gross margin down $4 million, partially offset by $0.7 million lower operating expenses and $0.4 million lower income tax.

• Cash and cash equivalents dropped to $1.3 million from $7 million as of July 31, 2025.

• $7.7 million used in operating activities over six months, offset by $2 million from private placements.

Outlook and guidance

• Transitioning to a focused biopharmaceutical strategy centered on Thykamine™.

• Pivotal clinical study for Thykamine™ in radiodermatitis prevention is a top priority.

• Ongoing preclinical studies for Thykamine™ in MASH and fibrosis.

• Actively evaluating strategic alternatives for the Altius business and seeking financing to support the pipeline.